{"product_id":"mesenchymal-stem-cell-therapy-for-multiple-sclerosis-what-a-new-review-of-eight-studies-found","title":"Mesenchymal Stem Cell Therapy for Multiple Sclerosis: What a New Review of Eight Studies Found","description":"\u003cp\u003eThis systematic review examined whether mesenchymal stem cell (MSC) therapy can rebalance the immune system in people with multiple sclerosis (MS). Across eight included studies, MSC treatment expanded regulatory T cells (Tregs) and suppressed T helper type 17 (Th17) cells, and many patients showed improvements in disability scores and MRI lesion burden. The therapy was generally safe, with mostly mild and self-limiting side effects, but the studies differed widely in cell source, delivery route, and outcome measures, and sample sizes were small.\u003c\/p\u003e\n\n\u003ch1\u003eMesenchymal Stem Cell Therapy for Multiple Sclerosis: What a New Review of Eight Studies Found\u003c\/h1\u003e\n\n\u003ch2\u003eTable of Contents\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003e\u003ca href=\"#ddn-key-points\"\u003eKey Points\u003c\/a\u003e\u003c\/li\u003e\n\n  \u003cli\u003e\u003ca href=\"#background\"\u003eBackground: Why This Research Matters\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#what-are-mscs\"\u003eWhat Are Mesenchymal Stem Cells?\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#immune-balance\"\u003eThe Immune Imbalance in Multiple Sclerosis\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#current-treatments\"\u003eCurrent Treatments and Their Limitations\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#study-methods\"\u003eHow This Review Was Conducted\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#search-strategy\"\u003eWhere the Researchers Searched for Studies\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#quality-assessment\"\u003eHow Study Quality Was Assessed\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#selection-results\"\u003eHow the Eight Studies Were Selected\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#key-findings\"\u003eKey Findings: Immune and Clinical Effects\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#clinical-implications\"\u003eWhat This Means for Patients\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#limitations\"\u003eLimitations: What the Review Could Not Prove\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#recommendations\"\u003eRecommendations and Future Directions\u003c\/a\u003e\u003c\/li\u003e\n  \u003cli\u003e\u003ca href=\"#ddn-faq\"\u003eFrequently Asked Questions\u003c\/a\u003e\u003c\/li\u003e\n\u003cli\u003e\u003ca href=\"#source\"\u003eSource Information\u003c\/a\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c!-- ddn:keypoints:start --\u003e\n\u003ch2 id=\"ddn-key-points\"\u003eKey Points\u003c\/h2\u003e\n\u003cul\u003e\n\u003cli\u003eIn eight reviewed studies, MSC therapy expanded regulatory T cells and suppressed T helper 17 cells, rebalancing the immune system in multiple sclerosis.\u003c\/li\u003e\n\u003cli\u003eImprovements in EDSS disability scores and MRI lesion burden were seen in a significant subset of patients, not all.\u003c\/li\u003e\n\u003cli\u003eMSC therapy was generally safe, with mostly mild and self-limiting side effects, unlike some immunosuppressive treatments that carry higher infection and tumor risks.\u003c\/li\u003e\n\u003cli\u003eStudies differed widely in MSC source, delivery route, and outcome measures, and sample sizes were small, limiting comparability.\u003c\/li\u003e\n\u003cli\u003eMSC therapy is not yet a proven standard treatment; larger studies with standardized protocols and control groups are needed.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c!-- ddn:keypoints:end --\u003e\n\n\n\u003ch2 id=\"background\"\u003eBackground: Why This Research Matters\u003c\/h2\u003e\n\u003cp\u003eMultiple sclerosis (MS) is an inflammatory disease in which the immune system attacks the central nervous system (the brain and spinal cord). The disease damages myelin, the protective coating around nerve fibers, and this damage leads to nerve degeneration over time.\u003c\/p\u003e\n\u003cp\u003eMS is the most common non-traumatic cause of disability in young adults. It affects more than 2.8 million people worldwide, and the number of new cases has risen notably in recent decades.\u003c\/p\u003e\n\u003cp\u003eEarlier research showed that immune dysregulation in MS mainly comes from myelin-specific autoreactive CD4+ T cells. These are immune cells that mistakenly target the body's own myelin. This process is strongly linked to immune dysfunction, temporary activation of immune cells, and an imbalance in the ratios of different immune cell subpopulations.\u003c\/p\u003e\n\u003cp\u003eDespite notable progress in recent decades, a proven cure for MS remains elusive. The available treatments have drawbacks that limit their use in clinical settings because of undesirable side effects.\u003c\/p\u003e\n\n\u003ch2 id=\"what-are-mscs\"\u003eWhat Are Mesenchymal Stem Cells?\u003c\/h2\u003e\n\u003cp\u003eMesenchymal stem cells (MSCs) are a type of non-hematopoietic stem cell, meaning they are not the blood-forming stem cells found in bone marrow. MSCs are distinguished by their ability to self-renew.\u003c\/p\u003e\n\u003cp\u003eSince their initial extraction from bone marrow, MSCs have been found in several other tissues. These tissues include the periendothelium (the tissue surrounding blood vessels), adipose tissue (fat tissue), the epidermis (outer skin layer), and umbilical cord blood.\u003c\/p\u003e\n\u003cp\u003eWhen exposed to suitable stimuli, MSCs can differentiate into cells of diverse mesenchymal lineages. These include osteoblasts (bone-forming cells), chondrocytes (cartilage cells), fibroblasts (connective tissue cells), and adipocytes (fat cells).\u003c\/p\u003e\n\u003cp\u003eMSCs can display diverse surface markers and cytokine profiles, and these characteristics are influenced by the tissue the cells come from. MSCs play a crucial role in preserving immunological and vascular balance, and they also assist the hematopoietic stem cells in bone marrow.\u003c\/p\u003e\n\u003cp\u003eMSCs can migrate selectively to areas of tissue injury or inflammation. This process is known as \"homing.\" MSCs are accessible as either autologous (from the patient) or allogeneic (from a donor) somatic stem cells. Therefore, MSCs have been the subject of extensive research across various disease models.\u003c\/p\u003e\n\u003cp\u003eMSCs possess significant immunomodulatory properties and exhibit low immunogenicity (a low tendency to trigger an immune rejection response). For these reasons, researchers regard MSCs as a crucial resource for managing the progression of MS and re-establishing immune tolerance.\u003c\/p\u003e\n\u003cp\u003eMSCs substantially enhance both innate and adaptive immune responses because of their anti-inflammatory, anti-apoptotic (cell-protecting), and immunomodulatory qualities. The immunomodulatory effects may result from direct interactions with immune cells or through paracrine signaling mechanisms, in which MSCs release signaling molecules that affect nearby cells.\u003c\/p\u003e\n\n\u003ch2 id=\"immune-balance\"\u003eThe Immune Imbalance in Multiple Sclerosis\u003c\/h2\u003e\n\u003cp\u003eWhen naive CD4+ T cells become activated, they differentiate into several helper subsets. These subsets include T helper type 1 (Th1) cells, T helper type 2 (Th2) cells, T helper type 17 (Th17) cells, and regulatory T (Treg) cells.\u003c\/p\u003e\n\u003cp\u003eTwo changes are especially important in MS. First, Th17 cells show heightened pro-inflammatory effects. Second, Tregs show a reduced ability to suppress immune activity. Together, these changes are essential elements contributing to the breakdown of immune tolerance in MS.\u003c\/p\u003e\n\u003cp\u003eThis imbalance between Th17 cells and Treg cells is a central target of new treatment research. A deeper understanding of the possible mechanisms behind MSC-mediated Th17\/Treg homeostasis is necessary to support the creation of novel MSC-based treatments.\u003c\/p\u003e\n\n\u003ch2 id=\"current-treatments\"\u003eCurrent Treatments and Their Limitations\u003c\/h2\u003e\n\u003cp\u003eAt present, numerous immunotherapies are available, and they aim to restore the balance of Th17 and Treg cells in MS. These include a range of disease-modifying therapies (DMTs) and immunosuppressive agents.\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eInterferon beta (IFN-β)\u003c\/li\u003e\n  \u003cli\u003eGlatiramer acetate (GA)\u003c\/li\u003e\n  \u003cli\u003eTeriflunomide\u003c\/li\u003e\n  \u003cli\u003eFingolimod\u003c\/li\u003e\n  \u003cli\u003eSeveral monoclonal antibodies that employ cell depletion strategies\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eIn MS patients, these DMTs and monoclonal antibodies have somewhat alleviated the Th17\/Treg imbalance. However, these medication therapies are nonspecific and suppress the systemic immune system. They carry a higher risk of infection, tumors, and other negative effects.\u003c\/p\u003e\n\u003cp\u003eThe primary objectives of most currently available therapeutic approaches are to reduce symptoms, reduce the rate at which disability develops, avoid relapses, and limit disability accumulation. These approaches are based on the prescription of immunosuppressive and immune-modulating treatments.\u003c\/p\u003e\n\u003cp\u003eRecent studies have shown that MSCs possess strong immunomodulatory potential, which makes them extremely promising options for the management of inflammatory autoimmune diseases. Novel treatments such as MSC therapy have demonstrated encouraging outcomes in addressing severe MS.\u003c\/p\u003e\n\u003cp\u003eThese advanced therapies provide renewed hope for patients who have not adequately responded to traditional treatment methods. They may work by repairing injured nerve cells and halting the progression of the disease.\u003c\/p\u003e\n\u003cp\u003eRecent randomized controlled trials (RCTs) have demonstrated the neuroprotective and immunomodulatory effects of MSC therapy. These effects include an impact on cerebrospinal fluid (CSF) biomarkers, which in turn influence the progression of the disease.\u003c\/p\u003e\n\u003cp\u003eAlthough MSCs are known to modulate immune responses, their exact mechanisms remain unclear. This is particularly true for how MSCs regulate the Th17\/Treg axis in MS. Addressing these gaps is essential for advancing targeted therapies and improving clinical outcomes.\u003c\/p\u003e\n\n\u003ch2 id=\"study-methods\"\u003eHow This Review Was Conducted\u003c\/h2\u003e\n\u003cp\u003eThe researchers conducted this systematic review by precisely following the 2020 guidelines for the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA).\u003c\/p\u003e\n\u003cp\u003eThe team selected studies according to the elements of Participants, Intervention, and Outcomes (PIO). The participants were MS patients. The intervention was stem cells, specifically MSCs. The outcome was immune response, measured as an immunomodulatory outcome measure.\u003c\/p\u003e\n\u003cp\u003eThe inclusion criteria encompassed English-language full-text articles disseminated within the preceding five years. The included study types were RCTs, systematic reviews, observational studies, meta-analyses, and reviews. The exclusion criteria comprised case reports, case studies, and editorials.\u003c\/p\u003e\n\u003cp\u003eThe researchers opted to include systematic reviews, meta-analyses, and narrative reviews because the number of such works in this field is limited.\u003c\/p\u003e\n\n\u003ch2 id=\"search-strategy\"\u003eWhere the Researchers Searched for Studies\u003c\/h2\u003e\n\u003cp\u003eThe team systematically searched PubMed, PubMed Central (PMC), the Cochrane Library, Google Scholar, and ClinicalTrials.gov. They looked for relevant studies published up to March 24, 2025.\u003c\/p\u003e\n\u003cp\u003eThe search strategy included combinations of Medical Subject Headings (MeSH) and free-text keywords. The key terms were \"Multiple Sclerosis,\" \"Mesenchymal Stem Cells,\" \"Immunomodulation,\" and related terms. Boolean operators and database-specific filters were applied, including full text, English language, and the last five years.\u003c\/p\u003e\n\u003cp\u003eThe searches returned the following numbers of results:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003ePubMed: 231 results, with filters of last five years and free full text\u003c\/li\u003e\n  \u003cli\u003eCochrane Library: 19 results, with a 2020-2025 filter\u003c\/li\u003e\n  \u003cli\u003eGoogle Scholar: 122 results, with a 2020-2025 filter\u003c\/li\u003e\n  \u003cli\u003ePMC: 55 results, with filters of open access and five years\u003c\/li\u003e\n  \u003cli\u003eClinicalTrials.gov: 5 results, with a 2020-2025 filter\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAll relevant articles were imported into EndNote (Clarivate, Philadelphia, PA, USA). The references were grouped and alphabetized using Microsoft Excel 2021 (Microsoft Corp., Redmond, WA, USA) for duplicate removal.\u003c\/p\u003e\n\u003cp\u003eEach identified article underwent a preliminary screening process that involved examining titles and abstracts. After eligible articles were identified, the researchers evaluated the availability of their full texts. The most pertinent papers were assessed based on the predetermined inclusion and exclusion criteria.\u003c\/p\u003e\n\u003cp\u003eAny disagreements between the reviewers during study selection or quality assessment were initially resolved through discussion. If consensus could not be reached, a third independent reviewer was consulted to reach a final decision.\u003c\/p\u003e\n\n\u003ch2 id=\"quality-assessment\"\u003eHow Study Quality Was Assessed\u003c\/h2\u003e\n\u003cp\u003eThe researchers evaluated the remaining full articles for quality and risk of bias using specific tools tailored to each type of study. Each assessment tool had distinct criteria and scoring systems.\u003c\/p\u003e\n\u003cp\u003eA score of one point was awarded for ratings of \"LOW RISK,\" \"YES,\" \"PARTIAL YES,\" or \"1.\" Two points were assigned for a score of \"2.\" A minimum score of 70% was required for acceptance from each assessment tool. The researchers chose the \u0026gt;70% threshold to ensure inclusion of studies with acceptable methodological quality, consistent with practices in prior systematic reviews.\u003c\/p\u003e\n\u003cp\u003eThe tools used were:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003e\n\u003cstrong\u003eCochrane Collaboration Risk of Bias Tool (CCRBT)\u003c\/strong\u003e for RCTs. This tool examines seven factors. The factors are random sequence generation and allocation concealment (selection bias). The factors are selective reporting of outcomes (reporting bias). The factors are other sources of bias. The factors are blinding of participants and personnel (performance bias). The factors are blinding of outcome assessment (detection bias). The factors are incomplete outcome data (attrition bias). Each type of bias is rated as LOW RISK, HIGH RISK, or UNCLEAR.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eJoanna Briggs Institute (JBI) Critical Appraisal Checklist\u003c\/strong\u003e for quasi-experimental studies. This checklist has nine key considerations. These include whether the study clearly defines cause and effect. These include whether participants were in comparable groups. These include whether a control group was present. These include whether outcomes were measured reliably. These include whether the statistical analysis was appropriate. Responses were categorized as YES, NO, UNCLEAR, or NOT ACCEPTABLE.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eAssessment of Multiple Systematic Reviews 2 (AMSTAR 2)\u003c\/strong\u003e for systematic reviews and meta-analyses. This tool has 16 segments. The segments cover whether the review question included the PICO components. The segments cover whether review methods were decided in advance. The segments cover the thoroughness of the literature search. The segments cover duplicate study selection and data extraction. The segments cover risk of bias assessment. The segments cover funding disclosure. The segments cover appropriateness of statistical methods. The segments cover handling of heterogeneity. The segments cover exploration of publication bias. The segments cover disclosure of conflicts of interest. Items were rated as YES or NO, and a partial \"yes\" was taken into account.\u003c\/li\u003e\n  \u003cli\u003e\n\u003cstrong\u003eScale for the Assessment of Narrative Review Articles 2 (SANRA 2)\u003c\/strong\u003e for narrative reviews. This tool has six items. The items include description of the literature search, referencing, scientific logic, a statement of specific objectives or questions, justification of the article's relevance to the readership, and ideal data presentation. Items scored 0-1 or 2.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eAll RCTs assessed in the review used the CCRBT and exhibited a \"LOW RISK\" of bias concerning generating random sequences.\u003c\/p\u003e\n\u003cp\u003eThe JBI checklist was used to assess two quasi-experimental studies in the review. Item 4 was recorded as \"NO\" for both studies because there was no control or comparator group.\u003c\/p\u003e\n\u003cp\u003eThe two quasi-experimental studies were Cohen et al. (2023) and Jamali et al. (2024). Both studies met most of the nine JBI criteria:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eBoth identified the \"cause\" and the \"effect\" (Yes for both)\u003c\/li\u003e\n  \u003cli\u003eCohen et al. had no comparable participant groups (N\/A); Jamali et al. did (Yes)\u003c\/li\u003e\n  \u003cli\u003eCohen et al. did not have comparable care between groups (N\/A); Jamali et al. did (Yes)\u003c\/li\u003e\n  \u003cli\u003eNeither study used a control group (No for both)\u003c\/li\u003e\n  \u003cli\u003eBoth took repeated outcome measurements before and after the intervention (Yes for both)\u003c\/li\u003e\n  \u003cli\u003eBoth had thorough follow-up, with discrepancies justified and examined (Yes for both)\u003c\/li\u003e\n  \u003cli\u003eBoth measured participant results similarly in any comparisons (Yes for both)\u003c\/li\u003e\n  \u003cli\u003eBoth measured results accurately (Yes for both)\u003c\/li\u003e\n  \u003cli\u003eBoth applied proper statistical analysis (Yes for both)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eCohen et al. (2023) scored 7\/9 (100%) and Jamali et al. (2024) scored 8\/9 (100%). Both were included in the review.\u003c\/p\u003e\n\n\u003ch2 id=\"selection-results\"\u003eHow the Eight Studies Were Selected\u003c\/h2\u003e\n\u003cp\u003eThe initial number of relevant studies identified across the five databases was 432. EndNote removed 14 duplicate articles, automated tools removed six records, and four records were removed for other reasons.\u003c\/p\u003e\n\u003cp\u003eThe researchers performed an extensive review of 408 articles. This included a thorough examination of titles and abstracts, as well as an evaluation of full-text accessibility.\u003c\/p\u003e\n\u003cp\u003eAs a result, 39 articles were chosen for retrieval, while 369 were eliminated from further consideration. After further assessment of the chosen studies, 11 reports were determined to be not retrievable. Ultimately, the team assessed 28 pertinent articles for eligibility and quality based on established appraisal criteria.\u003c\/p\u003e\n\u003cp\u003eThe researchers then excluded six studies with scores lower than 70%, 12 studies that were not open access, and two preclinical studies. As a result, eight pertinent articles were incorporated into the systematic review.\u003c\/p\u003e\n\u003cp\u003eArticles with favorable and unfavorable outcomes were selected to mitigate the risk of bias. The final selection comprised:\u003c\/p\u003e\n\u003cul\u003e\n  \u003cli\u003eTwo randomized controlled trials (RCTs)\u003c\/li\u003e\n  \u003cli\u003eTwo non-randomized experimental studies\u003c\/li\u003e\n  \u003cli\u003eThree systematic reviews with meta-analyses\u003c\/li\u003e\n  \u003cli\u003eOne narrative review\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe review describes these trials and reviews based on their outcomes, applicability, and limitations. The researchers used a narrative synthesis rather than performing a meta-analysis because of the inter-variability among studies. This variability included heterogeneity of participants, variety of interventions, and a range of outcome measures.\u003c\/p\u003e\n\u003cp\u003eData collected from each study included first author, year, study type, disease, inclusion and exclusion criteria, results, key findings, and funding sources. For clinical trials, the researchers also collected the sample size and demographics of research participants. The reviews addressed the total number of participants and the variety, quantity, and type of studies.\u003c\/p\u003e\n\n\u003ch2 id=\"key-findings\"\u003eKey Findings: Immune and Clinical Effects\u003c\/h2\u003e\n\u003cp\u003eFollowing MSC therapy in MS patients, the researchers found significant alterations in neuroprotective biomarker levels in the cerebrospinal fluid (CSF). These results were positive.\u003c\/p\u003e\n\u003cp\u003eOn the immune side, MSC therapy facilitated the expansion of regulatory T cells (Tregs). At the same time, the therapy suppressed T helper type 17 (Th17) cell activity. Together, these two effects restored immune balance and diminished neuroinflammation.\u003c\/p\u003e\n\u003cp\u003eClinically, improvements in Expanded Disability Status Scale (EDSS) scores and MRI lesion burden were observed in a significant subset of patients. The EDSS is a standard scale used to measure disability in MS, and MRI lesion burden refers to the amount of visible damage on brain and spinal cord scans.\u003c\/p\u003e\n\u003cp\u003eAcross the included studies, MSC therapy was generally safe. The adverse effects reported were mild and self-limiting, meaning they resolved on their own.\u003c\/p\u003e\n\u003cp\u003eHowever, the studies showed heterogeneity in several important areas. These areas included MSC sources, administration routes, and outcome measures. Along with small sample sizes, this heterogeneity limited comparability between studies.\u003c\/p\u003e\n\n\u003ch2 id=\"clinical-implications\"\u003eWhat This Means for Patients\u003c\/h2\u003e\n\u003cp\u003eMSC-based therapies show promising potential as a personalized approach to MS management. The review found evidence that MSC therapy can shift the immune system toward a more balanced state.\u003c\/p\u003e\n\u003cp\u003eSpecifically, the expansion of Tregs and the suppression of Th17 cells address the exact immune imbalance that drives MS. This suggests that MSC therapy targets a root mechanism of the disease, not just its symptoms.\u003c\/p\u003e\n\u003cp\u003eThe improvements in EDSS scores and MRI lesion burden are encouraging for patients. However, these improvements were observed in a significant subset of patients, not in all patients. This means some patients benefited and others did not.\u003c\/p\u003e\n\u003cp\u003eThe safety profile is also encouraging. Most side effects were mild and resolved without intervention. This contrasts with some existing immunosuppressive treatments, which carry higher risks of infection and tumors because they suppress the entire immune system.\u003c\/p\u003e\n\u003cp\u003eThat said, patients should understand that this review synthesizes early-stage evidence. The small sample sizes and differences between studies mean the results cannot yet be used to predict how any individual patient would respond to MSC therapy.\u003c\/p\u003e\n\n\u003ch2 id=\"limitations\"\u003eLimitations: What the Review Could Not Prove\u003c\/h2\u003e\n\u003cp\u003eThe review has several important limitations that patients and clinicians should keep in mind.\u003c\/p\u003e\n\u003cp\u003eFirst, the included studies were heterogeneous. They used different sources of MSCs, different routes of administration, and different outcome measures. This made it difficult to compare results across studies.\u003c\/p\u003e\n\u003cp\u003eSecond, the sample sizes were small. Small studies are more likely to show chance findings and are less reliable for drawing firm conclusions.\u003c\/p\u003e\n\u003cp\u003eThird, the two quasi-experimental studies had no control or comparator group. Without a control group, it is harder to know whether improvements were due to the treatment or to other factors.\u003c\/p\u003e\n\u003cp\u003eFourth, the researchers could not perform a meta-analysis, which is a statistical method for combining results from multiple studies. Instead, they used a narrative synthesis, which describes the studies without pooling their numbers.\u003c\/p\u003e\n\u003cp\u003eFifth, the exact mechanisms by which MSCs regulate the Th17\/Treg axis in MS remain unclear. Several unanswered questions regarding their mechanistic role highlight the need for further research.\u003c\/p\u003e\n\n\u003ch2 id=\"recommendations\"\u003eRecommendations and Future Directions\u003c\/h2\u003e\n\u003cp\u003eThe review's authors conclude that MSC-based therapies show promising potential as a personalized approach to MS management. However, they emphasize that more research is needed before these therapies become standard care.\u003c\/p\u003e\n\u003cp\u003eKey priorities for future research include:\u003c\/p\u003e\n\u003col\u003e\n  \u003cli\u003eLarger studies with more participants to confirm the findings and improve reliability.\u003c\/li\u003e\n  \u003cli\u003eStandardized protocols for MSC sources, administration routes, and outcome measures, so results can be compared across studies.\u003c\/li\u003e\n  \u003cli\u003eControlled study designs, including control groups, to distinguish treatment effects from other factors.\u003c\/li\u003e\n  \u003cli\u003eDeeper investigation into the exact mechanisms by which MSCs regulate the Th17\/Treg balance in MS.\u003c\/li\u003e\n  \u003cli\u003eDevelopment of novel MSC-based treatments targeted at more accurate immune-molecular interventions.\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cp\u003eFor patients, the practical takeaway is that MSC therapy is an active and promising area of research, but it is not yet a proven standard treatment. Patients who have not responded adequately to traditional treatments may wish to discuss clinical trial opportunities with their neurologist.\u003c\/p\u003e\n\n\u003c!-- ddn:faq:start --\u003e\n\u003ch2 id=\"ddn-faq\"\u003eFrequently Asked Questions\u003c\/h2\u003e\n\u003ch3\u003eWhat is mesenchymal stem cell therapy for multiple sclerosis?\u003c\/h3\u003e\n\u003cp\u003eMesenchymal stem cells (MSCs) are non-blood-forming stem cells found in bone marrow, fat tissue, umbilical cord blood and other tissues. They can self-renew, migrate to areas of injury or inflammation, and have immunomodulatory properties. In multiple sclerosis, MSC therapy is being studied for its ability to rebalance the immune system by expanding regulatory T cells and suppressing T helper 17 cells.\u003c\/p\u003e\n\u003ch3\u003eDoes MSC therapy actually improve disability or MRI lesions in MS?\u003c\/h3\u003e\n\u003cp\u003eAcross eight included studies, improvements in Expanded Disability Status Scale (EDSS) scores and MRI lesion burden were observed in a significant subset of patients, not all. The review also found that MSC therapy expanded regulatory T cells and suppressed T helper 17 cells, restoring immune balance and reducing neuroinflammation. However, small sample sizes and differences between studies mean these results cannot predict how any individual patient would respond.\u003c\/p\u003e\n\u003ch3\u003eWhat are the side effects or risks of MSC therapy for MS?\u003c\/h3\u003e\n\u003cp\u003eIn the eight studies reviewed, MSC therapy was generally safe. Reported adverse effects were mostly mild and self-limiting, meaning they resolved on their own without intervention. This contrasts with some existing immunosuppressive treatments, which carry higher risks of infection and tumors because they suppress the entire immune system. However, the review synthesizes early-stage evidence, so longer-term safety data are still limited.\u003c\/p\u003e\n\u003ch3\u003eWho might be eligible for MSC therapy, and is it available now?\u003c\/h3\u003e\n\u003cp\u003eMSC therapy is not yet a proven standard treatment for multiple sclerosis. The review included patients with MS who had not adequately responded to traditional treatments, but eligibility criteria varied across studies. Patients interested in MSC therapy may wish to discuss clinical trial opportunities with their neurologist. More research, including larger studies with standardized protocols and control groups, is needed before these therapies become standard care.\u003c\/p\u003e\n\u003ch3\u003eHow is MSC therapy given, and how often?\u003c\/h3\u003e\n\u003cp\u003eThe included studies used different sources of MSCs, different routes of administration, and different outcome measures. Because of this heterogeneity, the review could not determine a single standard approach for how MSC therapy is given or how often. The authors emphasize that standardized protocols for MSC sources, administration routes, and outcome measures are a key priority for future research so results can be compared across studies.\u003c\/p\u003e\n\u003ch3\u003eWhat does an EDSS score mean in the context of MSC therapy?\u003c\/h3\u003e\n\u003cp\u003eThe Expanded Disability Status Scale (EDSS) is a standard scale used to measure disability in multiple sclerosis. In the eight studies reviewed, improvements in EDSS scores were observed in a significant subset of patients after MSC therapy. However, because the studies were small and heterogeneous, these improvements cannot be used to predict how any individual patient would respond to treatment.\u003c\/p\u003e\n\u003ch3\u003eWhy can't the review prove MSC therapy works for MS?\u003c\/h3\u003e\n\u003cp\u003eThe review could not prove MSC therapy works because the included studies were heterogeneous, using different MSC sources, administration routes, and outcome measures. Sample sizes were small, and two quasi-experimental studies had no control or comparator group. The researchers could not perform a meta-analysis and instead used a narrative synthesis. The exact mechanisms by which MSCs regulate the Th17\/Treg axis also remain unclear.\u003c\/p\u003e\n\u003ch3\u003eIf I have multiple sclerosis and my neurologist recommends disease-modifying therapy, when should I seek a second opinion about mesenchymal stem cell therapy?\u003c\/h3\u003e\n\u003cp\u003eMSC therapy is an active area of research, not a proven standard treatment for MS. The evidence comes from eight small, heterogeneous studies with differing cell sources, delivery routes, and outcome measures, and two studies lacked control groups. Improvements in disability scores and MRI lesion burden appeared in a subset of patients, not all. A second opinion can help clarify whether standard disease-modifying therapy or a clinical trial is appropriate for your situation. Diagnostic Detectives Network provides independent expert second opinions.\u003c\/p\u003e\n\u003c!-- ddn:faq:end --\u003e\n\n\u003ch2 id=\"source\"\u003eSource Information\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eOriginal article title:\u003c\/strong\u003e Immunomodulatory Role of Mesenchymal Stem Cell Therapy in Multiple Sclerosis: A Systematic Review.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthors:\u003c\/strong\u003e Amin MN, Hashish R, Agha Tabari K, Swami SS, Kasagga A, Assefa AK, Yu AK.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003ePublication details:\u003c\/strong\u003e Cureus, published June 29, 2025, Volume 17, Issue 6, article e86988. DOI: 10.7759\/cureus.86988. This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eAuthor affiliations:\u003c\/strong\u003e California Institute of Behavioral Neurosciences \u0026amp; Psychology (Fairfield, USA); Sherwood Forest Hospitals NHS Foundation Trust (Nottingham, UK); Queen Elizabeth University Hospital (Glasgow, UK); Peking University (Beijing, China); University Hospitals of Leicester NHS Trust (Leicester, UK).\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eNote:\u003c\/strong\u003e This patient-friendly article is based on peer-reviewed research. It restructures the findings of one systematic review for a general audience. It is not medical advice, and patients should consult their healthcare provider about any treatment decisions.\u003c\/p\u003e","brand":"DiagnosticDetectives.Com","offers":[{"title":"Default Title","offer_id":47828029407388,"sku":null,"price":0.0,"currency_code":"RUB","in_stock":true}],"url":"https:\/\/diagnosticdetectives.ru\/products\/mesenchymal-stem-cell-therapy-for-multiple-sclerosis-what-a-new-review-of-eight-studies-found","provider":"DiagnosticDetectives.Com","version":"1.0","type":"link"}